<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16519">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01760109</url>
  </required_header>
  <id_info>
    <org_study_id>2002HL0153</org_study_id>
    <nct_id>NCT01760109</nct_id>
  </id_info>
  <brief_title>Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection</brief_title>
  <acronym>PIP-SBT</acronym>
  <official_title>Phase IV Study on Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangbei Welman Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangbei Welman Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the proposed study, the investigators plan to evaluate the efficacy and safety of
      Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for the treatment of respiratory
      and urinary tract acute bacterial infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Piperacillin sodium and sulbactam sodium for injection (2:1)plays a therapeutic role by the
      former inhibiting bacterial cell wall synthesis，the latter making irreversible competitive
      inhibition of β-lactamase.The antimicrobial effect of Piperacillin can be enhanced by the
      two combined. The compound specifically aims to the mechanism of bacterial resistance,
      extending the life of Piperacillin in the treatment-resistant pathogen infections.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The rate of bacterial clearance</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
    <description>end of treatment of bacteriological efficacy(bactercial clearance) The fore-and-aft changes of clinical symptoms and signs after discontinuation of durgs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>two years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the incidence(%)of allergies, skin rashes, shock,death, etc.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Piperacillin Sodium and Sulbactam Sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:xintemie 1.5-3.0g,iv,bid 7-14 days
serious infections 6.0-12.0g,iv,tid for 7-14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin Sodium and Sulbactam Sodium</intervention_name>
    <description>1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days</description>
    <arm_group_label>Piperacillin Sodium and Sulbactam Sodium</arm_group_label>
    <other_name>xin te mie</other_name>
    <other_name>te mie jun</other_name>
    <other_name>xin ke jun</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients who qualify for moderate and severe acute respiratory or urinary tract
             bacterial infection of acute bacterial infections need for systemic antibiotic
             therapy.

          2. Age&gt;18 years old, Gender: both

          3. Women of childbearing age were to be negative pregnancy test and agree to take
             contraceptive measures during the trial;

          4. patients were volunteers and signed informed consent form;

          5. patients did not participate in other clinical trials.

        Exclusion Criteria:

          1. Patients were hypersusceptibility to the test drug or other penicillins ,β-lactamase
             inhibitor

          2. Pregnant and Lactating women

          3. Patients have severe liver,kidney,cardiovascular,cerebrovascular,endocrine and
             hematopoietic system of primary diseases and that of immunodeficiency,advanced cancer
             or mental illness.

          4. Patients who were complicated by other diseases and thought to affect efficacy
             evaluations or poor compliance.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changqing Li, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chongqing Red Cross Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ting Wang, doctor</last_name>
    <phone>020-38868707</phone>
    <email>wmrd@welman.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rong Lin, bachelor</last_name>
    <phone>020-38868707</phone>
    <email>linrong@welman.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chongqing Red Cross hospital</name>
      <address>
        <city>Chongqing</city>
        <zip>400020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changqing Li, doctor</last_name>
      <phone>(023)88519201</phone>
    </contact>
    <investigator>
      <last_name>Changqing Li, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 30, 2012</lastchanged_date>
  <firstreceived_date>December 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory and urinary tract infections</keyword>
  <keyword>Piperacillin Sodium and Sulbactam Sodium for Injection (2:1)</keyword>
  <keyword>Phase IV</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Sulbactam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
